of Murine B16 Melanoma Cytokine Products on the Pulmonary Metastasis A Pathogenic Role of Th2 Cells and Their
暂无分享,去创建一个
[1] X. Cheng,et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. , 1997, Journal of immunology.
[2] A. Dalgleish,et al. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. , 1996, Gene therapy.
[3] D. Herndon,et al. Interleukin‐12 protects thermally injured mice from herpes simplex virus type 1 infection , 1996, Journal of leukocyte biology.
[4] A. Sochanik,et al. Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. , 1995, Cancer letters.
[5] D. Longo,et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. , 1995, Journal of the National Cancer Institute.
[6] Makiko Kobayashi,et al. CD4+ contrasuppressor T cells improve the resistance of thermally injured mice infected with HSV , 1995, Journal of leukocyte biology.
[7] G. Dranoff,et al. Gene therapy of metastatic cancer by in vivo retroviral gene targeting , 1995, Nature Genetics.
[8] A. McAdam,et al. Synergistic effects of co‐expression of the Th1 cytokines il‐2 and IFNγ on generation of murine tumor‐reactive cytotoxic cells , 1995, International journal of cancer.
[9] A. Kehlen,et al. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell‐derived cytokines, such as IL‐4 and IL‐13 , 1995, Clinical and experimental immunology.
[10] I. Schmidt-Wolf,et al. Cytokines and clinical gene therapy , 1995, European journal of immunology.
[11] T. Tamiya,et al. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. , 1995, Human gene therapy.
[12] T. Eberlein,et al. Immunoregulatory effects of CD4+ T helper subsets in human melanoma. , 1995, Surgery.
[13] J. Krauss,et al. Enhancement of Immune Reactivity in the Lymph Nodes Draining a Murine Melanoma Engineered to Elaborate Interleukin‐4 , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[14] R. Fisher,et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[15] A. Sher,et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[16] E. Thiel,et al. Interleukin-4 inhibits growth of a human lung-tumor cell-line in-vitro and has therapeutic activity against xenografts of this cell-line in-vivo. , 1993, International journal of oncology.
[17] R. Martuza,et al. Treatment of glioma by engineered interleukin 4-secreting cells. , 1993, Cancer research.
[18] C. Hsieh,et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.
[19] G. Trinchieri,et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.
[20] R. Moy,et al. Local expression of antiinflammatory cytokines in cancer. , 1993, The Journal of clinical investigation.
[21] K. Ando,et al. Differential induction of prostaglandin E2‐dependent and ‐independent immune suppressor cells by tumor‐derived GM‐CSF and M‐CSF , 1993, Journal of leukocyte biology.
[22] C. Lindqvist,et al. Decreased interleukin-2 beta-chain receptor expression by interleukin-4 on LGL: influence on the IL-2 induced cytotoxicity and proliferation. , 1992, Cancer letters.
[23] G. Gallagher,et al. Peritumoural IL-4 treatment induces systemic inhibition of tumour growth in experimental melanoma. , 1992, Anticancer research.
[24] A. Bitonti,et al. Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. , 1992, Cancer research.
[25] F. Luscinskas,et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. , 1992, Journal of immunology.
[26] S. Sone,et al. Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state. , 1991, Cancer research.
[27] M. Kasahara,et al. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. , 1991, Journal of immunology.
[28] S. Mizel,et al. Partial purification of an immunosuppressive protein from a human tumor cell line and analysis of its relationship to transforming growth factor beta. , 1989, Cellular immunology.
[29] P. Leder,et al. Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.
[30] M. Awwad,et al. The immune response to tumors. , 1989, Transplantation proceedings.
[31] I. Nabi,et al. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. , 1988, Cancer research.
[32] Z. L. Herd. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. , 1987, Cancer research.
[33] R. Pollard,et al. Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli. , 1986, Journal of the National Cancer Institute.
[34] B. Mukherji,et al. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. , 1986, Journal of immunology.
[35] V. Ling,et al. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. , 1984, Science.
[36] J. Werkmeister,et al. Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vivo , 1981, International journal of cancer.
[37] I. Fidler,et al. The pathogenesis of cancer metastasis , 1980, Nature.
[38] J. Vaage. Circulating tumor antigens versus immune serum factors in depressed concomitant immunity. , 1974, Cancer research.
[39] C. Casciani,et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.
[40] 西岡 安彦. Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state , 1993 .
[41] G. Haas,et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. , 1993, The Journal of clinical investigation.
[42] O. Yoshie,et al. Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D. , 1986, Japanese journal of cancer research : Gann.
[43] G Poste,et al. Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.